Dialog Box

Results of the CAVEATT trial for unresectable or metastatic type B3 thymomas and thymic carcinomas

The CAVEATT trial recruited 32 patients across 2 centres in Italy with an advanced stage of disease who had progressed after ≥1 line of platinum-based chemotherapy. 

All patients received a combination of fortnightly avelumab and twice daily axitinib until disease progression or toxicity thresholds were reached.

Promisingly, 34% of patients showed a partial response rate, 56% had stable disease, and 6% had progressive disease. No patients had a complete response rate and there were no treatment-related deaths.

Overall these results show that the combination of the anti-PD-L1 inhibitor avelumab and the anti-angiogenesis drug axitinib has the potential to be a new treatment option with acceptable toxicity for patients with with advanced type B3 thymoma and thymic carcinoma resistant to chemotherapy.

Learn more about the results

You can read the abstract and purchase the article here.

Read the article

11 November 2022
Category: News